Cytosorbents
CTSO | NASDAQ
$4.85
-$0.02 (-0.41%)
At close: Nov 16, 2026, 4:00 PM ET
$4.85
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Cytosorbents Company Profile
Company profile explainedCompany Profile
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Phillip Chan | Chief Executive Officer & Director |
| Peter J. Mariani | Chief Financial Officer |
| Vincent J. Capponi | President & Chief Operating Officer |
| Christian Steiner | Executive Vice President of Sales & Marketing |
| Christopher Cramer | Senior Vice President of Business Development |
| Efthymios N. Deliargyris FACC FESC FSCAI | Chief Medical Officer |
| Jodi Hoover | Executive |
| Kathleen Bloch | Advisor |
| Robert H. Bartlett | Co-Chairman of Cardiac Surgery Advisory Board & Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 08, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
Cytosorbents
| Country | United States |
| IPO Date | Aug 8, 2006 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 129 |
| CEO | Phillip Chan |
Contact Details
305 College Road East Princeton,
New Jersey 08540 United States
Stock Details
| Ticker Symbol | CTSO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001175151 |
| CUSIP Number | 23283X305 |
| ISIN Number | US23283X3052 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove CTSO